Pregled bibliografske jedinice broj: 4856
Osteogenic protein-1 (Bone morphogenetic protein-7) protects against renal injury following ischemia in rats
Osteogenic protein-1 (Bone morphogenetic protein-7) protects against renal injury following ischemia in rats // Second International Conference on Bone Morphogenetic Proteins / Reddi, Hari A. (ur.).
Sacramento (CA), 1997. str. 124-124 (pozvano predavanje, nije recenziran, sažetak, ostalo)
CROSBI ID: 4856 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Osteogenic protein-1 (Bone morphogenetic protein-7) protects against renal injury following ischemia in rats
Autori
Vukičević, Slobodan ; Bašić, Vanja ; Bašić, Nikolina ; Shepard, Alyssa ; Jin, Donald ; Shih, Mei-Shu ; Ryan, Susan ; Griffiths, Denise ; Norton, Karen ; Drager, Doug ; Costa, Doug ; Rogić, Dunja ; Bosukonda, Dattatreyamurty ; Jelić, Mislav ; Maliakal, John ; Jones, William ; Dorai, Haimanti ; Stavljenić, Ana ; Sampath, T. Kuber
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
Second International Conference on Bone Morphogenetic Proteins
/ Reddi, Hari A. - Sacramento (CA), 1997, 124-124
Skup
Second International Conference on Bone Morphogenetic Proteins
Mjesto i datum
Sacramento (CA), Sjedinjene Američke Države, 04.06.1997. - 08.06.1997
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Nije recenziran
Ključne riječi
OP-1 (BMP-7); renal injury
Sažetak
Osteogenic protein-1 (OP-1/BMP-7), a member of TGF-B superfamily of proteins, is required for the kidney development and OP-1/BMP-7 null mutation mice die shortly after birth due to renal failure. In the present study, we examined the ability of systemically administered recombinant human OP-1 to modulate the degree of injury following ischemia and reperfusion in rats. Pharmacokinetic studies indicate that high serum levels of OP-1 were achieved after IV injection followed by a steadily decline with a halflife of about 30 minutes. Bioavailability studies show that 125-I-OP-1 specifically bound to plasma membrane fractions of the kidney and about 140 and 270 ng OP-1/g of tissue was available to the medulla or cortex, respectively, when 250 ug/kg bw of 125-I-OP-1 was injected. Evaluation of therapeutic effects indicate that OP-1 significantly suppresses blood urea nitrogen and serum creatinine levels and effectively increases the survival rate when applied within 16 hours after injury. Additional histochemical and molecular analyses demonstrate that OP-1: 1) improves renal hemodynamic properties as shown by increased glomerular filtration rate, 2) maintains the integrity of vascular smooth muscle cells in the S3 zone as qualified by expression of smooth muscle alpha-actin, 3) suppresses inflammation by downregulating the expression of intercellular adhesive molecule, I-CAM, in vascular endothelium, 4) minimizes infarction and cell necrosis, and 5) reduces programmed cell death during the recovery phase. These data collectively indicate that OP-1 averts damage associated with ischemia and reperfusion to kidney and, as such, may provide a basis for the treatment of acute renal failure.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108241
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Vanja Bašić Kes
(autor)
Dunja Rogić
(autor)
Nikolina Bašić-Jukić
(autor)
Mislav Jelić
(autor)
Ana Stavljenić
(autor)